Dupilumab not checked
Regeneron · Sanofi · R668 · SAR231893
FollowEvery change as it happens, and a Monday email
Trials
26 active
82 in total · 30 in the EU
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- How it’s given
- “Each single-use pre-filled syringe with needle shield contains 300 mg dupilumab in 2 mL solution.”In the company’s words, NCT07905547 on ClinicalTrials.gov
- Tested for
- Asthma (3 trials), Dermatitis Atopic (2 trials), Eosinophilic Oesophagitis, Atopic Dermatitis, Chronic Obstructive Pulmonary Disease (COPD), Chronic Obstructive Pulmonary Disease, Pruritus, Prurigo Nodularis and 8 more
- Main trialPhase 4
- “This is parallel, Phase 4 study which consists of a 24 week (0.5 years) randomized, double blind, placebo controlled, 2-arm treatment period followed by an open label segment of 104 weeks (2 years) for a total of 128 weeks (2.5 years) to evaluate the effect of dupilumab treatment on esophageal function, and remodeling in adults with eosinophilic esophagitis. Duration of study period (per participant) * Screening period: Up to 12 weeks before Week 0 * Randomized double-blind period: 24 weeks * Open label period: 104 weeks * Post Investigational Medicinal Product (IMP) intervention follow-up…”In the company’s words, NCT06101095 on ClinicalTrials.gov
- Other names
- Dupixent · R668 · SAR231893 · REGN668 · SAR231893 Dupixent · SAR231893 + ALT-B4
Other drugs for Asthma
- BenralizumabAstraZeneca · Phase 3
- HFA-152aGSK · Phase 3
- MM09Inmunotek S.L. · Phase 3
- TEV-56248Teva Branded Pharmaceutical Products R&D, Inc. · Phase 3
- FF/UMEC/VIGSK · Phase 3
- 6103SBio · Phase 3
Copies tested against it3
Other companies’ versions, mostly cheaper copies for when the patent ends
- CKD-706Chong Kun Dang Pharmaceutical · NCT07358156
- IBI3027Innovent Biologics (Suzhou) Co. Ltd. · NCT07502534
- QL2108Qilu Pharmaceutical Co., Ltd. · NCT06884891, NCT06614907
Coming up12
- 7 Feb 2027Phase 4 trial completes · ClinicalTrials.gov
- 16 Mar 2027Phase 4 trial completes · ClinicalTrials.gov
- 24 Apr 2027Phase 4 trial completes · ClinicalTrials.gov
- 29 Apr 2027Phase 4 trial completes · ClinicalTrials.gov
- 2 Jun 2027Phase 3 trial completes · ClinicalTrials.gov
- 31 Aug 2027Phase 1 trial completes · ClinicalTrials.gov
- 28 Oct 2027Phase 3 trial completes · ClinicalTrials.gov
- 2 May 2028Phase 3 trial completes · ClinicalTrials.gov
- 19 Jun 2028Phase 3 trial completes · ClinicalTrials.gov
- 30 Jul 2028Phase 4 trial completes · ClinicalTrials.gov
- 21 Dec 2028Phase 3 trial completes · ClinicalTrials.gov
- 23 Dec 2028Phase 4 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials82
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Active, not recruiting | 5 Nov 2025 | A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial) | |
| Phase 4Not yet recruiting | 7 Feb 2027 | A Study to Investigate Dupixent/ Dupilumab in Adult Indian Participants With Moderate-to-severe Atopic Dermatitis | |
| Phase 4Active, not recruiting | 16 Mar 2027 | Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma | |
| Phase 4Active, not recruiting | 24 Apr 2027 | Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma | |
| Phase 4Active, not recruiting | 29 Apr 2027 | A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis | |
| Phase 4Recruiting | 30 Jul 2028 | This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring Hospitalization | |
| Phase 4Recruiting | 23 Dec 2028 | A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease. | |
| Phase 3Recruiting | 2 Jun 2027 | Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC) | |
| Phase 3Recruiting | 28 Oct 2027 | A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis | |
| Phase 3Not yet recruiting | 2 May 2028 | Pharmacokinetics, Immunogenicity and Safety of Subcutaneous Dupilumab and Berahyaluronidase Alfa (ALT-B4) Coformulation | |
| Phase 3Recruiting | 19 Jun 2028 | A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis | |
| Phase 3Enrolling by invitation | 21 Dec 2028 | Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS) | |
| Phase 2Active, not recruiting | 23 Feb 2026 | A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have | |
| Phase 2Active, not recruiting | 13 May 2026 | A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab)) | |
| Phase 1Active, not recruiting | 31 Aug 2027 | Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy | |
| Phase 4Completed | 17 Jun 2021 | Dupilumab Skin Barrier Function Study in Atopic Dermatitis | |
| Phase 4Completed | 6 Oct 2021 | SAR231893-LPS15497- "Dupilumab Effect on Sleep in AD Patients" | |
| Phase 4Completed | 30 Jun 2022 | Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis | |
| Phase 4Completed | 7 Sep 2022 | Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic Dermatitis | |
| Phase 4Completed | 21 Dec 2022 | Dupilumab in Japanese Patients With Chronic Rhinosinusitis With Nasal Polyp (SINUS-M52) | |
| Phase 4Completed | 26 Jun 2023 | The Effect of Dupilumab on Lung Inflammation and Related Changes in Airway Volumes Detectable by Functional Respiratory Imaging in Patients With Moderate-severe Asthma | |
| Phase 4Completed | 15 Jul 2023 | A Study to Evaluate the Effect of Dupilumab on Exercise Capacity in Adult Patients With Asthma | |
| Phase 4Completed | 3 Oct 2023 | A Phase 4, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Persistent Asthma | |
| Phase 4Completed | 22 Dec 2023 | Dupilumab-pediatric Skin Barrier Function and Lipidomics Study in Patients With Atopic Dermatitis in China | |
| Phase 4Completed | 25 Jan 2024 | Dupilumab Skin BArrier Function and LIpidomics STudy in Atopic Dermatitis in China | |
| Phase 4Completed | 16 Oct 2024 | EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients | |
| Phase 4Completed | 14 Nov 2024 | Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial | |
| Phase 4Withdrawn | 23 Dec 2027 | Study of Growth and Bone Mineral Density in Children With Atopic Dermatitis (AD) Treated With Dupilumab | |
| Phase 3Completed | 11 Oct 2019 | Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE) | |
| Phase 3Completed | 14 Feb 2020 | Evaluation of Dupilumab in Chinese Adult Patients With Moderate to Severe Atopic Dermatitis | |
| Phase 3Completed | 26 Aug 2020 | Evaluation of Dupilumab in Children With Uncontrolled Asthma | |
| Phase 3Completed | 30 Aug 2021 | Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2) | |
| Phase 3Completed | 9 Sep 2021 | Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE) | |
| Phase 3Completed | 12 Nov 2021 | Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME) | |
| Phase 3Completed | 14 Dec 2021 | Dupilumab in Japanese Patients With Atopic Dermatitis | |
| Phase 3Completed | 18 Feb 2022 | Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up) | |
| Phase 3Completed | 21 May 2022 | Efficacy and Safety Study of Dupilumab in Patients With Persistent Asthma | |
| Phase 3Completed | 2 Jun 2022 | Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE) | |
| Phase 3Completed | 27 Jun 2022 | Open-label Study of Dupilumab in Patients With Atopic Dermatitis | |
| Phase 3Completed | 31 Aug 2022 | A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT) | |
| Phase 3Completed | 2 Feb 2023 | Dupilumab for the Treatment of Chronic Inducible Cold Urticaria in Patients Who Remain Symptomatic Despite the Use of H1-antihistamine (LIBERTY-CINDU CUrIADS) | |
| Phase 3Completed | 8 Feb 2023 | Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation | |
| Phase 3Completed | 28 Feb 2024 | Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation | |
| Phase 3Completed | 1 Aug 2024 | Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID) | |
| Phase 3Completed | 6 Sep 2024 | Dupilumab in Chinese Adult Participants With CRSwNP | |
| Phase 3Completed | 11 Nov 2024 | A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥2 Years to <12 Years of Age With Uncontrolled Chronic Spontaneous Urticaria (CSU) (LIBERTY-CSU CUPIDKids) | |
| Phase 3Completed | 14 Dec 2024 | Dupilumab in Allergic Fungal Rhinosinusitis (AFRS) | |
| Phase 3Completed | 1 Apr 2025 | Assessment of the Safety and Efficacy of Dupilumab in Children With Asthma (Liberty Asthma Excursion) | |
| Phase 3Completed | 8 Jun 2026 | A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2) | |
| Phase 3Completed | 8 Jun 2026 | A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1) | |
| Phase 3Completed | 9 Oct 2026 | Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD) | |
| Phase 2/3Completed | 8 Jul 2021 | Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL) | |
| Phase 2/3Completed | 12 Jul 2024 | A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid | |
| Phase 2Completed | 3 Jan 2018 | Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma | |
| Phase 2Completed | 21 Mar 2019 | Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants | |
| Phase 2Terminated | 13 Mar 2020 | Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis | |
| Phase 2Completed | 16 Oct 2020 | Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy) | |
| Phase 2Completed | 19 Feb 2021 | Study to Evaluate Dupilumab Monotherapy in Pediatric Patients With Peanut Allergy | |
| Phase 2Completed | 27 Jul 2023 | Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED) | |
| Phase 2Completed | 14 Nov 2023 | Dupilumab in CRSsNP | |
| Phase 1Completed | 17 Jan 2015 | A Study to Investigate the Pharmacokinetics, Tolerability and Safety of Two Different Dupilumab Drug Products in Healthy Participants | |
| Phase 1Completed | 30 Mar 2015 | A Study to Investigate the Pharmacokinetics (PK), Tolerability and Safety of Two Different Dupilumab Drug Products in Healthy Participants. | |
| Phase 1Completed | 24 Sep 2021 | Single Dose Comparability Study of New and Current Dupilumab Drug Products Subcutaneously Administered in Healthy Adults | |
| Phase 1Completed | 30 Sep 2026 | Pharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Berahyaluronidase Alfa and Dupilumab Without Berahyaluronidase Alfa in Healthy Participants | |
| Phase 4Ended | not given | Dupilumab step-down strategy to maintain remission in adult and adolescents patients with atopic dermatitis: a non-inferiority randomized trial | |
| Phase 4Ended | not given | Treatment of rhinosinusitis with nasal polyposis with dupilumab and mepolizumab: A randomized, multi-centre, head-to-head comparison in real-world Danish patients | |
| Phase 4Ended | not given | A phase IV, randomized double blinded placebo-controlled study on the barrier restoring capacity of Dupilumab in type 2 airway disease: CRSwNP | |
| Phase 4Authorised | not given | DUPI REDUCE trial (DUPIlumab dose REDUCtion in patients with controlled atopic Eczema): a multicenter, low-intervention, non-inferiority randomized controlled trial, embedded in the TREAT NL registry. | |
| Phase 3Authorised | not given | BIomarker-dRiven Dosing Interval Extension of biologics in asthma (the BIRDIE trial) | |
| Phase 4Authorised | not given | Optimization of atopic dermatitis treatment that requires second-line systemic therapy through multiomic predictive models of treatment response (DermAtOmics-II) | |
| Phase 4Authorised | not given | Dupilumab treatment in patients with chronic rhinosinusitis with nasal polyps: the effect on comorbid eosinophilic otitis media | |
| Phase 3Authorised | not given | The use of dupilumab in treatment of indolent systemic mastocytosis with skin involvement | |
| Phase 4Ended | not given | Effect of Dupilumab on nasal epithelial barrier function in patients with Chronic Rhinosinusitis with nasal polyps (CRSwNP) – an exploratory pilot study | |
| Phase 2Ended | not given | An investigator-initiated, multi-center, randomized, double-blind, placebo controlled study of Dupilumab to demonstrate efficacy in subjects with nummular eczema | |
| Phase 4Authorised | not given | WIthdrawal of DUpilumab in Severe Asthma : a randomised non-inferiority-controlled trial | |
| Phase 3/4Ended | not given | Effect of Dupilumab an mucus plugs and inflammatory patterns in sEvere asThmAtiC paTients — a Pilot Study (DETACT) | |
| Phase 4Authorised | not given | English title: Complete remission study Subtitle: Discontinuation of Mepolizumab or Dupilumab after at least 12 months without symptoms in patients with severe Chronic rhinosinusitis with polyps – a National Danish RCT study. | |
| Phase 4Authorised | not given | English Title: Tapering of biologics in CRSwNP Subtitle: Tapering of Mepolizumab or Dupilumab after 12 months of complete or partial disease control in patients with severe chronic rhinosinusitis with nasal polyposis – a national Danish RCT. | |
| Phase 4Ended | not given | Long-term effect of Dupilumab on acetylsalicylic acid (ASA) intolerance and its mechanisms in patients with non-steroidal anti-inflammatory drug-exacerbated respiratory disease (N-ERD) | |
| Phase 4Authorised | not given | Direct comparison of Tezepelumab and Dupilumab in CRSwNP in a real world setting | |
| Phase 4Authorised | not given | BIOlogical treatment GRAdual Interval Longing in severe Asthma (BIO-GRAIL) | |
| Phase 4Authorised | not given | Optimization of Dupilumab Maintenance Dosing in Eosinophilic Esophagitis: A Phase IV, Randomized, Controlled, Single-Blind, Non-Inferiority Study |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026